Abstract: Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

Abstract: Methods are described for treating an influenza viral infection or associated diseases, disorders or mechanisms in a subject, comprising administering to the subject a therapeutically effective amount of a catecholic butane of the general formula (I) or a pharmaceutically acceptable salt thereof: wherein R1 and R2 each independently represents a hydrogen, a lower alkyl, a lower acyl, an alkylene, or —OR1 and —OR2 each independently represents an unsubstituted or substituted amino acid residue or pharmaceutically acceptable salt thereof; R3, R4, R5, R6, R10, R11, R12 and R13 each independently represents a hydrogen, or a lower alkyl; and R7, R8 and R9 each independently represents a hydrogen, —OH, a lower alkoxy, a lower acyloxy, an unsubstituted or substituted amino acid residue or pharmaceutically acceptable salt thereof, or any two adjacent groups together may be an alkyene dioxy; with the proviso in certain circumstances that where one of R7, R8 and R9 represents a hydrogen, then —OR1, —OR2 and the oth

Abstract: The present invention is a composition and method for treating oral lesions. A composition for treatment of oral lesions may comprise: (a) an anesthetic composition; (b) an antifungal composition; (c) a steroid composition; (d) an antihistamine composition; and (e) an antacid composition, wherein the therapeutic composition is substantially free of alcohol. A method for treatment may comprise: (a) administering to a patient an effective amount of a composition, the therapeutic composition comprising: (i) an anesthetic composition; (ii) an antifungal composition; (iii) a steroid composition; (iv) an antihistamine composition; and (v) an antacid composition, wherein the therapeutic composition is substantially free of alcohol. A method of producing a composition may comprise: combining (a) an anesthetic composition, (b) an antifungal composition, (c) a steroid composition, (d) an antihistamine composition, and (e) an antacid composition, wherein the therapeutic composition is substantially free of alcohol.

Abstract: The present invention relates to a fluvastatin-containing tablet, particularly a fluvastatin-containing tablet which has excellent disintegrating property and good bioavailability.

Abstract: A compound represented by the following formula (I) or a salt thereof which has excellent antitumor activity and angiogenesis inhibitory action in a low oxygen condition, and a medicament such as an antitumor agent and an anti-inflammatory agent which comprises the compound or a physiologically acceptable salt thereof as an active ingredient.

Abstract: The present application describes deuterium-enriched gabexate mesylate, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.

Abstract: The present invention relates to the use of nitric oxide releasing compounds for retarding or reversing muscular dystrophies such as Duchenne and Becker dystrophies.

Abstract: The present invention provides crystalline forms of Cinacalcet Fumarate and Cinacalcet Succinate, pharmaceutical compositions comprising the crystalline form of Cinacalcet Fumarate and/or the crystalline form of Cinacalcet Succinate, and processes for preparing the crystalline forms of Cinacalcet Fumarate and Cinacalcet Succinate and pharmaceutical compositions comprising the crystalline forms.

Abstract: The present invention relates to a therapeutic agent or prophylactic agent for a disease accompanying an abnormality in an amount of insulin or insulin response, an insulin-mimetic action agent, a food, beverage, or feed, an agent for enhancement of glucose uptake into a cell, and an agent for inducing differentiation into an adipocyte, each comprising as an effective ingredient at least one compound selected from the group consisting of specified compounds having an insulin-mimetic action, derivatives thereof, and pharmacologically acceptable salts thereof.

Abstract: The present application describes deuterium-enriched pravastatin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.

Abstract: The present invention relates to orally effective ligands of the peripheral cannabinoid receptor CB2, especially (+)-?-pinene derivatives, and to pharmaceutical compositions thereof, which are useful for prevention, alleviation or treatment of autoimmune neurodegenerative disorders, in particular multiple sclerosis and associated symptoms. Methods of the invention are useful when the active ingredient is administered alone or in combination with existing therapeutic modalities. The compositions are administered by oral route.

Abstract: A polymer of aspirin is provided by the present invention. Methods of making and using the same are also provided.

Abstract: The present invention relates to heparin-binding calixarene compounds of general Formula (I) in which R, R1, L and n have the meanings indicated in the description and their use in the biomedical field.

Abstract: The present invention provides a method of reducing or inhibiting osteoclast development induced by the receptor for activation of nuclear factor kappa B ligand (RANKL), comprising the step of contacting said osteoclast, or a precursor of the osteoclast, with a pharmacologically effective dose of compounds such as diferuloylmethane, guggulsterone, 1?-Acetoxychavicol or analogues thereof.

Abstract: The present invention relates to a process for preparing a ginger fraction, the fraction prepared by this process and the use thereof on its own or combined with drugs for inhibiting human cytochrome P450 (CYP) enzymes (particularly cytochrome P450 3A4, CYP3A4) for positively influencing the oral bioavailability and pharmacokinetics of active substances.

Abstract: The present invention provides pure pravastatin compositions and pure compactin compositions, and methods for the preparation thereof.

Abstract: Pamoic acid or its derivatives of formula (I) are used to treat diseases characterized by deposits of amyloid aggregates.

Abstract: This present invention provides methods and pharmaceutical compositions for the treatment or prophylaxis of diabetes and related disorders, comprising the administration of an effective amount of a monoester of probucol, particularly the monosuccinic acid ester, or a pharmaceutically acceptable salt or derivative thereof.

Abstract: The present invention relates to novel compounds of Formula (I), to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases.

Abstract: The present invention concerns methods of making physically stable aqueous suspensions of sparingly soluble to insoluble in water, active pharmaceuticals. More particularly, the invention provides an aqueous pharmaceutical suspension composition comprising an active pharmaceutical component which is sparingly soluble to insoluble in water; a water soluble, low viscosity grade cellulose polymer with a viscosity range of 3 mPa·s to 50 mPa·s as a surfactant; a suspending agent; and water.

Abstract: The present invention is directed to water-soluble derivatives of 2,6-diisopropylphenol (Propofol). The compounds act as prodrugs of 2,6-diisopropylphenol and metabolize rapidly to Propofol thereby providing an alternative to the water-insoluble 2,6-diisopropylphenol. Pharmaceutical compositions comprising these compounds, methods of induction and maintenance of anesthesia or sedation as well as methods of treating neurodegenerative diseases utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.

Abstract: This invention relates to compositions comprising co-crystals of (?)-gossypol with a C1-8 carboxylic acid or C1-8 sulfonic acid which are useful as inhibitors of Bcl-2 family proteins. The invention also relates to the use of co-crystals of (?)-gossypol with a C1-8 carboxylic acid or C1-8 sulfonic acid for inducing apoptosis in cells and for sensitizing cells to the induction of apoptotic cell death.

Abstract: Stabilized pharmaceutical compositions comprising polymorphs of active pharmaceutical ingredients susceptible to conversion to alternate polymorph forms are prepared by a process of wet granulation in which the ratios of active, fillers, and granulating liquid are controlled in order to avoid polymorphic interconversions.

Abstract: Ibopamine malcate salt (1:1), method for preparing it and pharmaceutical composition containing it.

Abstract: Once a day modified release oral dosage form comprising of granules or pellets which are either compressed into tablet or filled inside the capsule, wherein the pellet has a core of active ingredient coated on non pareil seeds with a rate controlling functional coating of co-polymer of polyvinyl acetate optionally with an intermediate separating coating between the core and the functional coating layer.

Abstract: A lipid composition includes triacylglycerols that include unsaturated fatty acids such as alpha linolenic acid and antioxidant moeities such as pyruvic acid.

Abstract: Acetyl-L-carnitine (ALCAR) and L-carntine (LCAR) are nutraceuticals with indications in treating a variety of mental health disorders. A metabolomics-guided bioprocess method is presented to enhance ALCAR and LCAR formation in germinating plant seeds. Metabolic fluxes are manipulated by germination in bioreactors to increase oxygen availability as well as provide an aseptic environment to alter carbohydrate consumption and feedback repress gluconeogenesis. Large shifts in sunflower seed fatty acid, phospholipid and high-energy metabolism change the germination environment and these metabolic changes lead to an approximate 1000-fold increase in natural LCAR and ALCAR production by the seeds. The resulting LCAR and ALCAR products from the seeds are used for treating mental health disorders including Alzheimer's disease, geriatric depression, non-geriatric depression and schizophrenia.

Abstract: A method for suppressing expression of PTX3 gene, which comprises administering an effective amount of a compound, which is represented by the following formula (1): wherein R1 represents an organic group, X represents —CH2CH2— or —CH?CH—, and R2 represents a hydrogen atom or an alkyl group, or a lactone derivative thereof, or a salt thereof. According to the present invention, a PTX3 gene expression suppressing method useful for the treatment of autoimmune diseases, especially rheumatoid arthritis can be provided.

Abstract: Provided for use in medical care settings is a gel preparation for oral administration to patients with hyperlipemia or hypercholesterolemia, wherein the ingestibility of an HMG-CoA reductase inhibitor, also known as a statin-series compound, has been improved in dosage forms of tablets, granules and liquids. A pharmaceutical composition in a gel form, comprising an HMG-CoA reductase inhibitor or a pharmaceutically acceptable salt thereof, a gelling agent, a polymer compound, a buffering agent, a preservative, a sweetening agent, a base and water, wherein the bad tastes of the statin-series compound are disguised, syneresis during storage is less likely, form retention is good, removal from containers is easy, and the ingestibility has been improved.

Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative represented by Formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the therapeutic and/or phrophylactic treatment of, inter alia, actinic keratosis.

Abstract: The present invention refers to the use of the compound of Formula (I?) or pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of hematological dyscrasias, including myelodisplastic syndromes (MDSs) and for improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy. In addition, it relates to the use of a compound of formula (I?) for the treatment and/or prophylaxis of cancer of an organ.

Abstract: The present invention relates to the use of a compound of Formula (I?) or pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of any of the diseases selected from the group consisting of benign prostatic hyperplasia, Barrett's disease, asthma, skeletal muscle and tendon repair, Crohn's disease, ulcerative colitis and leishmaniasis.

Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, rosacea.

Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, psoriasis.

Abstract: This invention is directed to a novel pharmacological property of ?-Amyrin acetate derived from Tabernaemontana dichotoma as a potent ?-glycosidase inhibitor, which has not been reported before. The present discovery also provides for the use of this compound as a new oral hypoglycemic drug in the treatment of type II diabetes being approximately 35 times potent compared with Acarbose, a standard drug widely prescribed to type II diabetes patients.

Abstract: Methods of utilizing a combined administration or a unit dosage of a combination of an HMG-CoA inhibitor and omega-3 fatty acids for the reduction of apolipoprotein-B levels. The methods are especially useful in the treatment of patients with hypertriglyceridemia or hypercholesterolemia or mixed dyslipidemia, coronary heart disease (CHD), vascular disease, atherosclerotic disease and related conditions, and for the prevention or reduction of cardiovascular, cardiac, and vascular events.

Abstract: Clear aqueous compositions comprising water, a hydrophobic organic compound, and from about 2 to about 50 wt. % of a solubilizer are disclosed. The solubilizer is an alkali metal or alkaline earth metal salt of a monoester of a saturated C6-C20 alcohol and a saturated dicarboxylic acid. The monoester salts are remarkably effective for solubilizing a wide variety of hydrophobic organic compounds in water to provide aqueous compositions that have excellent stability and outstanding clarity. The compositions are valuable for the cosmetic, agrochemical, coatings, pharmaceutical, and flavor & fragrance industries.

Abstract: The present invention relates a composition having a high content of xanthophyll esters, where the xanthophyll ester component of the composition is comprised of a high proportion of trans-lutein esters. The present invention also provides methods of making and using such a composition.

Abstract: The invention provides novel scoring patterns for a wide variety of tablets that contain specific drugs or contain drugs in certain drug classes, and methods of treatment with layered tablets and fractional tablets derived from breaking said tablets.

Abstract: This invention relates to compositions comprising co-crystals of (?)-gossypol with a C1-8 carboxylic acid or C1-8 sulfonic acid which are useful as inhibitors of Bcl-2 family proteins. The invention also relates to the use of co-crystals of (?)-gossypol with a C1-8 carboxylic acid or C1-8 sulfonic acid for inducing apoptosis in cells and for sensitizing cells to the induction of apoptotic cell death.

Abstract: A process for obtaining a microscopic physical state of xanthophylls or oxycarotenoids derivatives forms such as diacetates or dipropionates derivatives, which are readily incorporated in the digestive system as micelles providing an improved bioavailability, as compared to the bioavailability of carotenoids that are ingested in diverse preparations that contain microscopic carotenoids crystals and a method for its application.

Abstract: The present invention provides carbohydrate analogs of the formula: wherein X is CH2, O, or NH, and R1-8 are independently H, a short hydrocarbon, a substituted amine, an alcohol, a substituted ether, a substituted amide, a substituted ketone, a substituted carboxylic acid, a short peptide, or a short oligosaccharide, Y is H, a short hydrocarbon, a short peptide, or a short oligosaccharide, and R9 is H, a short hydrocarbon, a substituted amine, an alcohol, a substituted ether, a substituted amide, a substituted ketone, a carboxylic acid, a short peptide, or a short oligosaccharide.

Abstract: The intranasal delivery of an effective amount of NGF inducers, such as clenbuterol, to the brain.

Abstract: The present invention relates to 3?,28-diacetoxy-18-oxo-19,20,21,29,30-pentanorlupan-22-oic acid methanol solvate, its use in medicine and processes for its preparation.

Abstract: Compositions and methods for enhancing the absorption of active agents across the mucosa of animal subjects are provided. Methods of administration and appropriate dosage forms are also provided.

Abstract: The present invention provides combinations of pharmaceutically active agents (i.e. statins and negatively charged phospholipids) for treating or preventing atherosclerosis or coronary artery disease (CAD) in mammals, and methods therefore. In particular, these combinations and methods find utility for achieving one or more of the following effects in a subject: (1) a reduction in plasma levels of low-density lipoprotein (LDL) cholesterol and very-low-density lipoprotein (VLDL) cholesterol; (2) an increase in plasma levels of high-density lipoprotein (HDL) cholesterol; and (3) a reduction in plasma levels of triglycerides.

Abstract: The present invention provides moronic acid derivatives of the general formula: which have antiviral activity, along with compositions containing the same and methods of use thereof.

Abstract: The present invention relates to pharmaceutical compositions comprising simvastatin or pharmaceutically acceptable salts, solvates, enantiomers or mixtures thereof, processes for preparing the same and methods of use and treatment.

Abstract: New polymorphic forms of pravastatin sodium are provided. Each of the new forms is selectively obtained by crystallization from different solvent systems, each solvent system having a protic component, and by controlling the rate of crystallization through temperature. The new polymorphic forms are suitable for use as active substances of pharmaceutical dosage forms for reduction of serum cholesterol levels in the bloodstream.

Abstract: A method for suppressing undesired viral growth in a host which comprises administering to the host an effective amount of a compound of the formula: wherein R1, R2, R3 and R4 are independently selected from the group consisting of HO—, CH3O— and CH3(C?O) O—. The method is exemplified by inhibiting Tat transactivation of a lentivirus and in suppressing Herpes simplex virus.